宜宾手术去眼袋的费用宜宾垫鼻子永久的多少钱,宜宾抽眼袋多少钱,宜宾做双眼皮多少钱定位,宜宾什么是水光嫩肤,宜宾双眼皮哪做的最好,宜宾隆鼻术要多少钱,宜宾全面部填充

BEIJING, March 3 (Xinhuanet) -- A new study suggested that regular use of painkiller ibuprofen may cut the risk of developing Parkinson's disease, according to Reuters reports.The research findings were published in the online edition of the journal Neurology on Wednesday and later will appear in the print edition on March 8.The study, which followed more than 136,000 U.S. men and women for six years, showed that people who took ibuprofen at least twice a week were 38 percent less likely to develop Parkinson's, a brain disorder that causes tremors and movement problems, compared to those who didn't take the pain reliever so often.Ibuprofen is sold in the U.S. as a non-steroidal anti-inflammatory drug (NSAID). But the study didn't prove that other NSAIDS, like aspirin or naproxen, could also cut the Parkinson's risk."Our study suggests ibuprofen could be a potential neuroprotective agent against Parkinson's," says lead researcher Dr. Xiang Gao from Harvard Medical School, "Protective effects are seen after taking ibuprofen two or more times a week. That's so-called regular use."However, he also warned that no proof has been found that ibuprofen itself can help ward off Parkinson's, and said that it's too early to recommend people to start taking ibuprofen to protect against the disorder.Gao said, "We just see an association, not some causal relationship."Besides, regular ibuprofen use has risks, like stomach bleeding and kidney damage.

BEIJING, Feb. 10 (Xinhua) -- The Chinese currency, or the yuan, on Thursday rose to a fresh high of 6.5849 against the U.S. dollar, according to the China Foreign Exchange Trading System.The central parity rate of the yuan, or RMB, was 1 basis point higher than the previous record of 6.585 set on Feb. 9, the previous trading day.The central parity rate has risen against the dollar for a three consecutive trading days.China's central bank announced on June 19 last year that it would further reform the yuan exchange rate formation mechanism to improve its flexibility.On China's foreign exchange spot market, the yuan can rise or fall 0.5 percent from the central parity rate each trading day.The central parity rate of the RMB against the U.S. dollar is based on a weighted average of prices before the opening of the market each business day.

WASHINGTON, April 4 (Xinhua) -- The U.S. National Aeronautics and Space Administration (NASA) announced on Monday that following discussions among the International Space Station partners on Sunday, it is delaying the launch of space shuttle Endeavour's STS- 134 mission to April 29 from April 19.The new launch time is set for 3:47 p.m. EDT (1947 GMT) on Friday, April 29."The delay removes a scheduling conflict with a Russian Progress supply vehicle scheduled to launch April 27 and arrive at the station April 29," NASA said in a statement.NASA managers will hold a Flight Readiness Review on Tuesday, April 19, to assess the team's readiness to support launch. An official launch date will be selected at the conclusion of the meeting.Endeavour will deliver to the space station a 2-billion-dollar, multinational particle detector known as the Alpha Magnetic Spectrometer.

BEIJING, May 24 (Xinhuanet) -- Facebook founder Mark Zuckerberg welcomed more kids to join in the social network site, according to International Business Times reports on Monday.He made this comment in the NewSchools Summit in California.Zuckerberg said Facebood can help young kids to learn from each other and acquire more knowledge about using the internet."That will be a fight we take on at some point," Zuckerberg said, "My philosophy is that for education you need to start at a really, really young age." At the moment, Facebook officially does not allow the children younger than 13 to sign up, since the Children's Online Privacy Protection Act (COPPA) forbids children under 13 from joining an online service which collects user information data.However it recently revealed that 7.5 million Facebook users were younger than that, accoding to a study released last week by Consumer Reports.Some experts suggested Facebook may not be in any position to provide that education in its current form. "The lessons of digital citizenship have to start young, but I don't feel that Facebook is the venue to have those lessons occur. A lot of missteps happen on that site without a lot of coaching." said Dr. Gwenn O'Keeffe, an expert on young children's education.

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.